Drug or treatment

Pemigatinib clinical trials

• 11Clinical trials
• 5Countries

Newest trials

All recruiting trials (11)

• Pemigatinib plus PD-1 inhibitor with or without chemotherapy in FGFR2 fusion/rearrangement-positive cholangiocarcinoma

  This study tests whether combining pemigatinib with a PD-1 inhibitor, with or without chemotherapy, helps people with advanced biliary tract cancer that has FGFR2 fusions.

  Recruiting Phase 2 Peking Union Medical College Hospital · Beijing · NCT07786766

• Alternating chemo-immunotherapy and FGFR inhibitor for FGFR-positive biliary tract cancer

  This phase 2 trial tests whether alternating gemcitabine/cisplatin with durvalumab and the FGFR2 inhibitor pemigatinib can help people with unresectable or metastatic biliary tract cancers that have FGFR alterations.

  Recruiting Phase 2 Ohio State University Comprehensive Cancer Center · Columbus, Ohio · NCT07780838

• Pemigatinib for advanced SDH‑deficient GIST

  This trial will try the oral drug pemigatinib in adults with advanced SDH‑deficient GIST to see if it controls tumor growth and what side effects occur.

  Recruiting Phase 2 Dana-Farber Cancer Institute · Boston, Massachusetts · NCT07434843

• Using pemigatinib to treat advanced pancreatic cancer with FGFR genetic changes

  This study is testing if a new drug called pemigatinib can help adults with advanced pancreatic cancer that has specific genetic changes feel better and possibly live longer.

  Recruiting at 109 sites Phase 2 Ohio State University Comprehensive Cancer Center · Birmingham, Alabama and 108 other locations · NCT06906562

• Pemigatinib plus durvalumab for previously treated advanced intrahepatic cholangiocarcinoma with FGFR2 fusion

  This will test whether combining the FGFR inhibitor pemigatinib with the immunotherapy durvalumab helps adults with advanced intrahepatic cholangiocarcinoma that has an FGFR2 fusion and who have already received prior treatment.

  Recruiting at 3 sites Phase 2 Hoosier Cancer Research Network · Birmingham, Alabama and 2 other locations · NCT06728410

• Using Pemigatinib to Treat Solid Tumors with FGFR Gene Alterations

  This study is testing if pemigatinib can help people with solid tumors that have FGFR gene changes, especially those with hard-to-treat cancers.

  Recruiting Phase 2 Unicancer · Brest and 5 other locations · NCT06653777

• Pemigatinib plus atezolizumab and bevacizumab for advanced FGFR2‑fusion cholangiocarcinoma

  This trial tests whether adding pemigatinib to atezolizumab and bevacizumab can help control advanced cholangiocarcinoma in patients whose tumors have an FGFR2 fusion.

  Recruiting Phase 1/2 M.D. Anderson Cancer Center · Houston, Texas · NCT06439485

• Combining two drugs to treat advanced dedifferentiated liposarcoma

  This study is testing if combining two drugs can help people with advanced dedifferentiated liposarcoma who haven't had success with other treatments.

  Recruiting at 4 sites Phase 2 Lund University Hospital · Oslo and 3 other locations · NCT06389799

• Combining Afatinib and Pemigatinib for Advanced Solid Tumors

  This study is testing a combination of two drugs, Afatinib and Pemigatinib, to see if they can safely help people with advanced solid tumors that have specific genetic changes.

  Recruiting Phase 1 Massachusetts General Hospital · Boston, Massachusetts · NCT06302621

• Using Pemigatinib for Advanced Gastrointestinal Cancer with FGFR Alterations

  This study is testing if a drug called Pemigatinib can help people with advanced gastrointestinal cancer that has certain genetic changes and hasn't worked with other treatments.

  Recruiting Phase 2 Tianjin Medical University Cancer Institute and Hospital · Tianjin, Tianjin Municipality · NCT05651672

• Using pemigatinib after chemotherapy for newly diagnosed acute myeloid leukemia

  This study is testing if adding a new drug called pemigatinib after standard chemotherapy can help people with newly diagnosed acute myeloid leukemia recover better and stay safe.

  Recruiting at 2 sites Phase 1 OHSU Knight Cancer Institute · Portland, Oregon and 1 other locations · NCT04659616

Quick answers

How many clinical trials of Pemigatinib are recruiting right now?

11, as of November 12, 2026. We update this list each time we refresh our data from ClinicalTrials.gov.

Where are these trials running?

In 5 countries. The most sites are in United States (7 trials), China (2 trials), Norway (1 trial), Sweden (1 trial), France (1 trial). Each study page lists its sites and which ones are recruiting.

What phases are they in?

Phase 2: 8, Phase 1: 2, Phase 1/2: 1. Trials with no phase listed are usually device, behavioural or observational studies.

How do I join one?

Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.

Find the studies that fit you

A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.

Describe your situation →